PMV PharmaceuticalsPMVP
PMVP
About: PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
Employees: 47
0
Funds holding %
of 7,363 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
505% more call options, than puts
Call options by funds: $115K | Put options by funds: $19K
1% more capital invested
Capital invested by funds: $58.2M [Q3] → $58.8M (+$678K) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
0.46% less ownership
Funds ownership: 75.75% [Q3] → 75.28% (-0.46%) [Q4]
5% less funds holding
Funds holding: 74 [Q3] → 70 (-4) [Q4]
40% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 10
52% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 31
Research analyst outlook
We haven’t received any recent analyst ratings for PMVP.
Financial journalist opinion
Based on 3 articles about PMVP published over the past 30 days
Neutral
Zacks Investment Research
6 days ago
Here's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom Fishing
PMV Pharmaceuticals (PMVP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Neutral
GlobeNewsWire
1 week ago
PMV Pharmaceuticals Reports Full Year 2024 Financial Results and Corporate Highlights
Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 90% of sites activated across the U.S., Europe, U.K., and Asia-Pacific; interim analysis data expected mid-2025 Enrollment commenced in the MD Anderson Cancer Center investigator-initiated Phase 1b study evaluating rezatapopt monotherapy and in combination with azacitidine in patients with relapsed or refractory AML/MDS harboring a TP53 Y220C mutation Cash, cash equivalents, and marketable securities of $183.3 million as of December 31, 2024 providing expected cash runway to end of 2026 PRINCETON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology clinical-stage company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the full year ended December 31, 2024, and provided a corporate update.
Neutral
GlobeNewsWire
4 weeks ago
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences
PRINCETON, N.J., Feb. 11, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the following investor conferences. Management will also participate in one-on-one investor meetings.
Positive
Zacks Investment Research
9 months ago
Here's Why PMV Pharmaceuticals (PMVP) Could be Great Choice for a Bottom Fisher
PMV Pharmaceuticals (PMVP) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Neutral
GlobeNewsWire
9 months ago
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
BOSTON and PRINCETON, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ: PMVP; “PMV Pharma”) today announced a partnership to develop Foundation Medicine's tissue-based comprehensive genomic profiling test, FoundationOne®CDx, as a companion diagnostic for PMV Pharma's rezatapopt, a first-in-class, investigational therapy for patients with locally advanced or metastatic solid tumors that have a TP53 Y220C mutation.
Neutral
Business Wire
9 months ago
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator
BOSTON & PRINCETON, N.J.--(BUSINESS WIRE)--Foundation Medicine and PMV Pharma partner to develop FoundationOne®CDx as a companion diagnostic for PMV Pharma's rezatapopt.
Neutral
GlobeNewsWire
10 months ago
PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights
PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
Neutral
GlobeNewsWire
11 months ago
PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors
PRINCETON, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that the first patient has been dosed in the registrational, tumor-agnostic PYNNACLE Phase 2 trial of rezatapopt (PC14586) in patients with advanced solid tumors harboring a TP53 Y220C mutation and KRAS wild-type (WT). Rezatapopt is a first-in-class precision oncology small molecule investigational therapy that selectively targets mutated p53 Y220C proteins in solid tumors.
Neutral
GlobeNewsWire
11 months ago
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer
PRINCETON, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that a Phase 1 analysis reported promising anti-tumor activity of rezatapopt (PC14586) in heavily pre-treated patients with advanced ovarian cancer harboring a TP53 Y220C mutation. Rezatapopt is a first-in-class precision oncology small molecule investigational therapy that selectively targets the TP53 Y220C mutation in solid tumors.
Neutral
GlobeNewsWire
1 year ago
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights
PRINCETON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.
Charts implemented using Lightweight Charts™